CorMedix Inc (CRMD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, CorMedix Inc (CRMD) has a cash flow conversion efficiency ratio of 0.233x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($94.46 Million) by net assets ($405.31 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See CorMedix Inc (CRMD) net asset quality to measure how much of total assets are equity-financed.
CorMedix Inc - Cash Flow Conversion Efficiency Trend (2008–2025)
This chart illustrates how CorMedix Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check CorMedix Inc (CRMD) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
CorMedix Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of CorMedix Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Grupo Supervielle S.A
F:189A
|
0.176x |
|
Shanghai Jin Jiang International Industrial Investment Co Ltd A
SHG:600650
|
0.032x |
|
Walton Advanced Engineering Inc
TW:8110
|
0.016x |
|
DBAPPSecurity Co Ltd
SHG:688023
|
0.004x |
|
Beijing StarNeto Technology Co Ltd
SHE:002829
|
-0.003x |
|
Yubico AB
ST:YUBICO
|
0.075x |
|
SmartFinancial, Inc.
NASDAQ:SMBK
|
0.031x |
|
Skandinaviska Enskilda Banken AB (publ)
ST:SEB-C
|
1.189x |
Annual Cash Flow Conversion Efficiency for CorMedix Inc (2008–2025)
The table below shows the annual cash flow conversion efficiency of CorMedix Inc from 2008 to 2025. For the full company profile with market capitalisation and key ratios, see CorMedix Inc market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $405.31 Million | $175.05 Million | 0.432x | +172.24% |
| 2024-12-31 | $84.66 Million | $-50.61 Million | -0.598x | -9.18% |
| 2023-12-31 | $70.14 Million | $-38.41 Million | -0.548x | -23.79% |
| 2022-12-31 | $55.06 Million | $-24.36 Million | -0.442x | -31.31% |
| 2021-12-31 | $62.80 Million | $-21.16 Million | -0.337x | +32.18% |
| 2020-12-31 | $44.22 Million | $-21.97 Million | -0.497x | +21.96% |
| 2019-12-31 | $23.65 Million | $-15.05 Million | -0.637x | +86.75% |
| 2018-12-31 | $4.93 Million | $-23.70 Million | -4.803x | -20.86% |
| 2017-12-31 | $7.19 Million | $-28.59 Million | -3.974x | -217.97% |
| 2016-12-31 | $17.81 Million | $-22.27 Million | -1.250x | -239.34% |
| 2015-12-31 | $34.01 Million | $-12.53 Million | -0.368x | +78.82% |
| 2014-12-31 | $3.63 Million | $-6.32 Million | -1.739x | -293.32% |
| 2013-12-31 | $-4.02 Million | $-3.62 Million | 0.900x | -81.21% |
| 2012-12-31 | $-475.38K | $-2.28 Million | 4.788x | +194.03% |
| 2011-12-31 | $1.24 Million | $-6.30 Million | -5.092x | -907.15% |
| 2010-12-31 | $7.26 Million | $-3.67 Million | -0.506x | -446.48% |
| 2009-12-31 | $-14.71 Million | $-2.15 Million | 0.146x | -57.32% |
| 2008-12-31 | $-12.03 Million | $-4.11 Million | 0.342x | -- |
About CorMedix Inc
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. CorMedix Inc. was formerly known as Pi… Read more